[
  {
    "question": "What factors seizures over syncope?",
    "option_a": "Cyanosis",
    "option_b": "Absence of tonic clonic",
    "option_c": "Percipitated by intense fear",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question asks for a distinguishing feature that favors seizures over syncope. Seizures and syncope both cause transient loss of consciousness, but their clinical presentations differ. In seizures, abnormal and excessive neuronal firing often results in features such as cyanosis, tongue biting, and postictal confusion, whereas syncope usually presents with prodromal symptoms and pallor. During a seizure, particularly a generalized tonic\u2010clonic event, excessive neuronal discharges lead to tonic contractions and possible apnea. This lack of effective breathing may result in cyanosis due to decreased oxygen saturation. In contrast, syncope, especially vasovagal syncope, is mediated by a transient decrease in cerebral perfusion without the prolonged postictal state and without significant oxygen desaturation that leads to cyanosis. Patients having seizures may appear cyanotic during or immediately after the event because of impaired respiration and sustained muscle activity. In syncope, the patients are typically pale due to vasovagal responses. The presence of cyanosis thus helps clinicians lean towards a seizure diagnosis if witnessed during the event. The differential diagnosis includes epileptic seizures, vasovagal syncope, cardiogenic syncope, and psychogenic non-epileptic events. A careful history, eyewitness accounts, and investigation (EEG for seizures, cardiac monitoring for syncope) help differentiate these conditions. Management of seizures involves establishing airway, breathing, circulation, and then initiating appropriate antiepileptic therapy if recurrent. In the acute setting, supportive care and careful observation are essential. In syncope, management targets the underlying cause (e.g., hydration, avoidance of triggers). Pregnancy and lactation considerations require careful drug choice, as many antiepileptics are associated with teratogenic risks, so minimizing exposure and using monotherapy when possible is advised. A: Cyanosis \u2013 Correct; it is a known feature favoring seizure activity due to oxygenation issues during convulsive activity. B: Absence of tonic clonic \u2013 Incorrect; the lack of tonic-clonic activity makes seizures less likely. C: Percipitated by intense fear \u2013 Incorrect; such a trigger is more typical in vasovagal syncope. D: (Blank) \u2013 Not applicable. 1. Tongue biting (especially lateral) and postictal confusion are highly suggestive of seizures. 2. Cyanosis during an episode is more common in seizures than in syncope. 3. Syncope is usually preceded by prodromal symptoms like lightheadedness and pallor. Recent studies and clinical guidelines emphasize a detailed history and eyewitness descriptions to differentiate seizures from syncope. The presence of cyanosis, while not exclusive, is one of several important clues that now supplements EEG and imaging studies in diagnosis.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Case of Epilepsy partialis continua, Rx?",
    "option_a": "IV diazepam",
    "option_b": "IV keppra",
    "option_c": "IV VPA",
    "option_d": "IV phenytoin",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Epilepsia partialis continua (EPC) is a rare and challenging form of focal status epilepticus characterized by continuous, focal motor seizures, often resistant to treatment. The initial goal in management is rapid seizure termination to prevent further neural injury. EPC results from persistent, focal cortical hyperexcitability. The abnormal electrical discharge, often due to structural lesions or autoimmune processes, leads to continuous jerking in a confined body region. Benzodiazepines, by potentiating GABAergic transmission, help in aborting the ongoing neuronal hyperactivity. Clinically, EPC presents as persistent, repetitive clonic movements limited to a part of the body, without a full-blown generalized seizure. Early recognition and treatment are crucial as prolonged seizures may lead to irreversible damage or functional deficits. Diagnosis is supported by an EEG demonstrating focal epileptiform discharges. Differential diagnoses include focal motor seizures from other causes, myoclonus, or even movement disorders. Neuroimaging typically helps to identify any underlying structural pathology. According to current status epilepticus guidelines, the first-line treatment is with intravenous benzodiazepines. IV diazepam, as used in this case, acts rapidly and is appropriate for the acute management of EPC. If seizures persist, second-line agents such as IV phenytoin, valproate (with caution in women of childbearing potential), or levetiracetam may be used. In pregnant or lactating patients, the teratogenic potential of drugs must be considered, further supporting the use of benzodiazepines and careful dosing adjustments. A: IV Diazepam \u2013 Correct; it is a rapid-acting benzodiazepine that potentiates GABA and is the standard first-line treatment in status epilepticus. B: IV Keppra (levetiracetam) \u2013 A viable second-line therapy, but not first-line. C: IV VPA \u2013 Effective but less preferred in women of reproductive age due to teratogenicity. D: IV Phenytoin \u2013 Again, a second-line option with more challenging pharmacokinetics. 1. EPC is a manifestation of focal status epilepticus with continuous clonic activity that requires prompt treatment. 2. Benzodiazepines are the first-line drugs in status epilepticus and are crucial in rapidly halting seizures. 3. In women of childbearing age, agents with lower teratogenic risks should be prioritized. Recent guidelines continue to endorse IV benzodiazepines as the first-line treatment in status epilepticus, including EPC. There is ongoing research into optimal second-line regimens, especially for treatment-refractory focal seizures, with pregnancy-safe protocols being an important consideration.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "case bout LKF (verbal auditoyry agnosia and progressive aphasia and found to have ESUS during sleep in his EEG. Dx?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "None",
    "subspecialty": "Epilepsy",
    "explanation": "This complex case presents with progressive language deficits (verbal auditory agnosia and progressive aphasia) combined with epileptiform discharges found during sleep on EEG. The challenge lies in integrating a degenerative or vascular process with findings suggestive of focal seizure activity. The progressive language impairment alongside epileptiform activity points toward a cortical process involving language networks. Chronic focal epileptic discharges can lead to excitotoxicity, which may contribute to a decline in language functions. This presentation does not align well with the discrete, acute deficits seen in embolic stroke or the classic neurodegeneration seen in primary progressive aphasia. In practice, a patient presenting with progressive aphasia and auditory processing difficulties with concurrent EEG abnormalities is more suggestive of a focal epilepsy that impacts language areas rather than a primary vascular event (ESUS) or a classic neurodegenerative disorder like primary progressive aphasia that lacks epileptiform discharges. Differentials include: ESUS, which would typically cause abrupt and focal neurologic deficits; Primary Progressive Aphasia (PPA), a neurodegenerative process without EEG seizures; stroke-induced auditory agnosia, which is usually acute; and functional aphasia, which lacks true EEG changes. A comprehensive evaluation with EEG, neuroimaging, and clinical history is essential. Management of such a case would focus on treating the underlying focal epilepsy with appropriate antiepileptic drugs and possibly immunomodulatory therapies if an autoimmune process is suspected. In pregnancy, for example, careful selection of antiepileptic drugs and dose adjustments are paramount; however, in this context, the key is recognizing the correct diagnosis to avoid inappropriate treatments. Tailoring treatment to minimize progression and neurotoxicity is critical. A: ESUS \u2013 Incorrect because an embolic stroke would cause an acute deficit rather than a slowly progressive language disorder accompanied by epileptiform EEG findings. B: Primary Progressive Aphasia \u2013 Does not account for the EEG seizure activity. C: Auditory Verbal Agnosia due to stroke or lesion \u2013 Typically presents acutely rather than progressively; also, it would not show the EEG epileptiform discharges noted. D: Functional (psychogenic) aphasia \u2013 Lacks EEG abnormalities and progressive neurological signs. Thus, none of the listed options appropriately fits the clinical scenario. 1. Progressive aphasia with EEG evidence of seizure activity should prompt suspicion for an epilepsy syndrome affecting language areas rather than a stroke or pure neurodegenerative process. 2. Always integrate clinical, EEG, and imaging findings when the presentation is complex. 3. ESUS and primary progressive aphasia have distinct temporal evolutions and do not typically present with sleep-related epileptiform discharges. Recent literature has emphasized the importance of recognizing atypical presentations of focal epilepsy, including those that mimic neurodegenerative disorders. Updated guidelines advocate for a comprehensive multimodal evaluation\u2014EEG, imaging, and clinical assessment\u2014to accurately discern these overlapping conditions.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "26 years old female, who is known to have epilepsy, had increased seizure frequency, and is pregnant and was on keppra 500mg BID, what to add?",
    "option_a": "Lamotrigine",
    "option_b": "VPA",
    "option_c": "Topomax",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question addresses the management of a pregnant woman with known epilepsy who is experiencing increased seizure frequency while on levetiracetam (Keppra). Pregnancy causes physiological changes that can alter the pharmacokinetics of antiepileptic drugs, thereby necessitating adjustments in therapy. During pregnancy, increased renal clearance and volume of distribution can lead to reduced serum concentrations of antiepileptic medications. Levetiracetam levels can fall below the therapeutic range, increasing the risk of breakthrough seizures. Lamotrigine, although also affected by pregnancy, has a well-established efficacy and safety profile in pregnant women when carefully monitored. For a woman with epilepsy, breakthrough seizures during pregnancy increase the risk of maternal injury and adverse fetal outcomes. Optimizing therapy is essential to maintain seizure control while minimizing drug exposure that could adversely affect the fetus. When a pregnant epileptic patient presents with increased seizures, it is important to assess medication levels, compliance, and potential pharmacokinetic changes due to pregnancy. Differentiating inadequate dosing versus increased metabolism is key. Differential considerations include noncompliance, drug interactions, or physiological changes altering drug levels. First-line management in pregnant patients with breakthrough seizures is to evaluate and adjust the dosing of the current drug. However, if monotherapy adjustments are insufficient, adding a second agent may be considered. Lamotrigine is often chosen as an add-on therapy because it is associated with lower teratogenic risks compared to valproate or topiramate. In all cases, careful monitoring of serum levels and dose adjustments throughout pregnancy is advised, along with preconception counseling and folic acid supplementation. A: Lamotrigine \u2013 Correct; it is a safe and effective add-on agent for seizure control in pregnancy with a lower teratogenic risk. B: VPA (valproic acid) \u2013 Incorrect; it is highly teratogenic and contraindicated in women of childbearing potential. C: Topomax (topiramate) \u2013 Incorrect; topiramate carries risks such as cleft lip/palate. D: (Blank) \u2013 Not applicable. 1. Monitor antiepileptic drug levels closely during pregnancy due to increased clearance. 2. Lamotrigine and levetiracetam are preferred in pregnancy because of their favorable safety profiles. 3. Avoid valproate in women of childbearing age due to its high teratogenicity. Recent guidelines and research underscore the importance of therapeutic drug monitoring during pregnancy. Lamotrigine is widely endorsed as a safe add-on option when seizure control is suboptimal, and polytherapy should be minimized to reduce teratogenic risk. Current studies also emphasize individualized dosing adjustments to maintain therapeutic levels throughout pregnancy.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Child brought to you with decrease in understanding of language and partial aphasia has recurrent seizures at night. EEG during sleep showed continuous spike and wave discharges, what is the most likely diagnosis? (Repeated twice with similar scenarios asking about the diagnosis in both)",
    "option_a": "Landau-kleffner syndrome",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Landau\u2010Kleffner syndrome (LKS) is a rare childhood disorder characterized by an acquired aphasia (especially in receptive language) and abnormal electroencephalogram (EEG) findings. It typically presents in preschool-aged children with speech and language regression alongside epileptiform activity. The underlying mechanism involves epileptiform discharges\u2014often localized to the temporal regions implicated in language processing\u2014which interfere with normal language acquisition and processing. During sleep, these discharges can become more continuous (continuous spike\u2010wave discharges), leading to disruption of neurodevelopmental processes; recent studies suggest that the abnormal electrical activity itself may contribute to ongoing cognitive and language deterioration. Clinically, children with LKS present with a gradual or sometimes sudden loss of receptive language abilities and, less commonly, expressive language. Seizures, particularly nocturnal ones, are common, and the EEG during sleep typically reveals continuous spike and wave discharges. This constellation of features directly ties the disruptive nighttime electrical activity to the daytime language deficits. The diagnosis is based on the clinical picture (acquired aphasia in a previously normal-developing child, often accompanied by seizures) and characteristic EEG findings during sleep. Differential diagnoses include other epileptic encephalopathies such as Continuous Spike-Wave during Slow-Wave Sleep (CSWS) syndrome and benign childhood epilepsy with centrotemporal spikes (BECTS), where language impairment is not as marked. Neuroimaging is usually normal, and additional evaluations aim to rule out alternative causes of language regression. Management is multifaceted, incorporating antiepileptic drugs (AEDs) to reduce seizure frequency and, ideally, the aberrant EEG discharges. First-line treatments include benzodiazepines (or other AEDs like valproate). There is also significant emphasis on intensive speech and language therapies. Some recent guidelines and expert reviews also discuss the potential role of corticosteroids for reducing inflammation and epileptiform activity. Although pregnancy and lactation considerations are more pertinent to adult patients, when using agents like valproate in women of childbearing age, careful consideration of teratogenicity is crucial. Option A (Landau\u2010Kleffner syndrome) is correct because the clinical scenario of acquired language regression, partial aphasia, nocturnal seizures, and continuous spike\u2010wave discharges during sleep is characteristic of LKS. The other options, though not listed, likely refer to alternative epilepsy syndromes that do not precisely match this combination of language regression and EEG findings. 1. Early recognition and treatment are important to maximize the potential for language recovery. 2. Continuous spike-and-wave activity during sleep is a key diagnostic EEG finding. 3. Multidisciplinary management including AEDs and speech therapy enhances outcomes. Recent research emphasizes the role of early treatment not only in controlling seizures but also in mitigating language regression. Updated guidelines recommend a tailored approach, often including trials of corticosteroids in refractory cases, and underscore the importance of regular EEG monitoring.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Child was seen in, during interview he had continuous jerks of right arm with few interruptions, what is the management?",
    "option_a": "IV Diazepam",
    "option_b": "IV Levetiracetam",
    "option_c": "IV Valproic acid",
    "option_d": "IV Phenytoin",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "The scenario describes a pediatric patient with continuous jerking of one limb, which is indicative of a focal motor seizure or a form of status epilepticus. In status epilepticus (prolonged or recurrent seizures without full recovery), rapid termination of seizures is critical to prevent neuronal injury. Status epilepticus results from an imbalance between excitatory and inhibitory neurotransmission in the brain. The continuous jerking, especially if it persists with few interruptions, indicates ongoing pathological neuronal firing. Benzodiazepines work by enhancing GABAergic (inhibitory) transmission, thereby helping to abort the seizure activity. The clinical presentation of persistent jerking of the right arm fits with focal motor status epilepticus. Rapid control of these seizures is necessary to prevent further neurological compromise and potential long-term deficits. Diagnosis is primarily clinical, supported by EEG findings if available. Differential diagnoses include movement disorders, focal motor epilepsy, and epilepsia partialis continua. Careful observation and history help differentiate ongoing focal seizures from other paroxysmal motor phenomena. According to current guidelines for status epilepticus, immediate treatment with a benzodiazepine is the first-line intervention. IV diazepam is a commonly used benzodiazepine in the acute setting. If seizures persist after benzodiazepine administration, second-line agents such as IV levetiracetam, valproic acid, or phenytoin may be considered. In pregnant or lactating patients, benzodiazepines are also first-line; however, potential effects on the fetus or breastfed infant should be discussed, and dosing should be carefully monitored. Option A (IV Diazepam) is correct because benzodiazepines are the established first-line treatment for status epilepticus in children. IV Levetiracetam (option B) and IV Valproic acid (option C) are generally used as second-line agents if initial benzodiazepine therapy fails, while IV Phenytoin (option D) is also considered second-line in pediatric status epilepticus management. 1. Benzodiazepines are the cornerstone of first-line status epilepticus management. 2. Rapid administration of IV diazepam can arrest seizure activity and prevent neuronal injury. 3. Always prepare for second-line therapy if seizures persist. Recent guidelines from leading neurological societies continue to support benzodiazepines as the first-line treatment for all forms of status epilepticus. Studies have shown that early intervention with these agents is crucial, and ongoing research is evaluating the optimal dosing strategies in the pediatric population, including in special populations such as pregnant and lactating women.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Three-month-old baby with early myoclonic encephalopathy with migrating myoclonic then became more generalized, EEG was done, what is expected to be seen?",
    "option_a": "2 Hz epileptic activity",
    "option_b": "Burst suppression",
    "option_c": "3 second spike and wave",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Early myoclonic encephalopathy is an epileptic encephalopathy that typically manifests in early infancy. It is characterized by prominent myoclonic seizures that may migrate from one region of the body to another and evolve into more generalized seizures, often with a grave neurodevelopmental prognosis. The condition is often linked with metabolic derangements (such as nonketotic hyperglycinemia) or genetic disorders. The hallmark EEG finding is a burst-suppression pattern, which reflects periods of high-amplitude activity (bursts) interspersed with nearly flat suppression phases. This pattern is indicative of widespread cortical dysfunction and disturbed neuronal networks. Clinically, the baby presents with migrating myoclonic jerks that can generalize over time, correlating with the chaotic electrical activity seen on EEG. The burst-suppression pattern is critical for distinguishing early myoclonic encephalopathy from other neonatal epileptic syndromes. The EEG is paramount in diagnosis, with burst-suppression being a key indicator. Differential diagnoses include Ohtahara syndrome, another early infantile epileptic encephalopathy that also displays a burst-suppression pattern; however, differences in seizure semiology (tonic versus myoclonic) and age of onset can help differentiate them. Management focuses on optimizing seizure control and addressing any underlying metabolic abnormalities. First-line antiepileptic treatments may vary depending on the etiology, but often include agents such as pyridoxine in suspected metabolic cases. Supportive care and extensive evaluation for inborn errors of metabolism are important. In the context of pregnancy and lactation, while this syndrome affects infants rather than pregnant women, treatment considerations for metabolic disorders in mothers (if hereditary) must be handled with multidisciplinary input. Option B (Burst suppression) is the correct answer. Option A (2 Hz epileptic activity) is more typical for conditions such as certain forms of generalized epilepsy. Option C (3-second spike and wave) aligns with childhood absence epilepsy, which is not seen in infants with this encephalopathy. The fourth option is not provided. 1. The burst-suppression EEG pattern is a devastating marker indicating severe cortical dysfunction. 2. Early myoclonic encephalopathy usually has a poor prognosis, making rapid metabolic evaluation critical. 3. Differentiation from Ohtahara syndrome is made based on seizure type and clinical context. Recent studies emphasize the importance of genetic and metabolic testing in infants with burst-suppression patterns on EEG. There is ongoing research into targeted therapies that might modify the course of severe epileptic encephalopathies, although current treatment remains largely supportive and symptomatic.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient presented to emergency with first onset seizure, exam was normal and brain MRI and EEG was normal, what is the risk of recurrence of seizure in 3 years?",
    "option_a": "10%",
    "option_b": "30%",
    "option_c": "50%",
    "option_d": "80%",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "After a first unprovoked seizure, determining the risk of recurrence is critical for guiding treatment decisions. This risk assessment is based on clinical characteristics and the results of investigations such as EEG and brain imaging. Seizure recurrence is influenced by intrinsic brain excitability that may be unmasked by an initial seizure event. Factors such as an underlying structural lesion, metabolic derangements, or subtle cortical dysplasias can increase this risk. Normal investigative studies (neurological exam, MRI, EEG) reduce, but do not eliminate, the inherent risk of recurrence. In patients with a normal exam, normal MRI, and normal EEG, there is a lower likelihood of an underlying brain pathology that predisposes to recurrent seizures. However, the recurrence risk remains significant and is one of the key considerations when deciding on initiating long-term antiepileptic therapy. The prognostic evaluation involves a detailed history, neurological examination, EEG, and neuroimaging. Differential considerations include provoked seizures (e.g., due to metabolic imbalances or infection) which have a different recurrence risk profile compared to unprovoked seizures. Current guidelines recommend that the decision to initiate antiepileptic therapy be based on the estimated risk of recurrence. A recurrence risk of approximately 30% over 3 years in patients with normal investigations is commonly accepted. First-line management involves risk stratification and discussing the benefits and risks of starting therapy. In adult women of childbearing age, and in pregnant or lactating patients, the potential teratogenicity of AEDs (such as valproate or phenytoin) must be considered, and alternatives with safer profiles should be chosen when possible. Option A (10%) underestimates the recurrence risk seen in first unprovoked seizures with normal evaluations. Option B (30%) is the more accurate estimate based on current literature. Option C (50%) and Option D (80%) overestimate the risk in patients with normal neurologic exam, EEG, and MRI findings. 1. Even with normal investigations, the recurrence risk after a first unprovoked seizure is significant, often around 30-40%. 2. Decisions regarding antiepileptic therapy should be individualized based on recurrence risk, patient lifestyle, and potential medication side effects. 3. Risk stratification is essential, particularly in women of childbearing age, to balance seizure control with medication safety. Recent meta-analyses and longitudinal cohort studies have confirmed that the recurrence risk after a first unprovoked seizure in patients with normal investigations is around 30%. This evidence supports guideline recommendations that advocate for careful patient counseling and consideration of observation versus initiation of therapy based on risk factors rather than a one-size-fits-all approach.",
    "exam_year": "2024",
    "exam_type": "Part II",
    "image_url": "page_8.png"
  },
  {
    "question": "Child with typical scenario of benign rolandic epilepsy , what is the finding on EEG?",
    "option_a": "Centrotemporal spikes",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Benign rolandic epilepsy (also known as benign childhood epilepsy with centrotemporal spikes or BCECTS) is an idiopathic focal epilepsy syndrome of childhood. It typically presents in children between 3 and 13 years of age with seizures that often occur during sleep and involve the face and oropharyngeal muscles. The disorder is believed to arise from transient hyperexcitability of the rolandic (sensorimotor) cortex, particularly the area corresponding to the face. Genetic predisposition and normal maturational changes in cortical excitability play significant roles. The typical EEG finding of centrotemporal spikes reflects this focal irritability in the sensorimotor regions. Clinically, children with benign rolandic epilepsy usually exhibit brief, focal seizures with twitching or numbness of the face, drooling, and sometimes speech arrest. Seizures often occur at night and may rarely generalize. The benign course and spontaneous remission by adolescence are hallmarks of the syndrome. Diagnosis is based on clinical history and EEG findings. Differential diagnoses include other childhood epilepsy syndromes such as Landau\u2010Kleffner syndrome (which has an acquired aphasia component) or occipital epilepsy (which features visual disturbances). A sleep EEG typically reveals high\u2010voltage centrotemporal spikes, which are activated during sleep. Given the typically benign and self-limited nature of the condition, many patients do not require daily medication unless seizures are frequent or disruptive. When treatment is needed, first-line therapies include carbamazepine or other narrow-spectrum sodium channel blockers. Owing to its benign nature, treatment decisions are individualized. In the context of pregnancy and lactation (though this is more pertinent later in life), most first-line agents used in children have well-established safety profiles. Option A (Centrotemporal spikes) is correct, as the EEG hallmark of benign rolandic epilepsy is the presence of centrotemporal spikes, particularly during sleep. Since other options are not provided, there is no conflict. 1) Centrotemporal (rolandic) spikes on EEG are pathognomonic for this condition. 2) Despite dramatic EEG findings, the syndrome usually has an excellent prognosis with spontaneous remission around puberty. Recent studies reaffirm the benign course of the syndrome and support conservative management in patients with infrequent seizures. Sleep-activated epileptiform discharges remain the distinguishing EEG feature, and the overall management strategy continues to emphasize individualized risk\u2013benefit analyses.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "18 years old male with epilepsy on Valproic acid and Topiramate, still uncontrolled. Found on in bed on prone position, announced dead upon arrival to ED. What increases the risk of death in epilepsy?",
    "option_a": "Generalized seizure",
    "option_b": "Sleep deprivation",
    "option_c": "MRI lesion",
    "option_d": "Focal changes on EEG",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Sudden Unexpected Death in Epilepsy (SUDEP) is a recognized complication in patients with epilepsy, particularly in younger patients with uncontrolled generalized tonic\u2010clonic seizures (GTCS). It is defined as the sudden, non\u2010traumatic death of a patient with epilepsy without a clear structural or toxicological cause. While the exact mechanism of SUDEP remains under investigation, it is thought that post-ictal autonomic dysfunction\u2014possibly involving respiratory compromise, cardiac arrhythmias, or central apnea following a generalized tonic-clonic seizure\u2014plays a key role. Seizures during sleep, especially in the prone position, further heighten this risk. In this case, the 18-year-old male with refractory epilepsy on valproic acid and topiramate who was found prone in bed and subsequently pronounced dead fits the typical picture of SUDEP. The strongest risk factor is the presence of uncontrolled generalized seizures. Diagnosis of SUDEP is made retrospectively after ruling out other causes of sudden death including cardiac, pulmonary, and metabolic causes. Differential diagnoses include accidental asphyxiation, drowning, or other sudden cardiac events. The clinical history of epilepsy and the circumstances surrounding the death are critical for diagnosis. The primary strategy for reducing SUDEP risk is optimal seizure control, particularly of generalized tonic-clonic seizures. This often entails titrating antiepileptic medications and considering adjunctive therapies or devices that monitor nocturnal seizures. Patients and caregivers should be counseled about the risks associated with sleeping in the prone position and the potential benefits of nighttime supervision. In pregnant patients, rigorous seizure control is essential both for reducing maternal risks and for protecting fetal well-being, as generalized seizures can have significant obstetric implications. Option A (Generalized seizure) is correct because uncontrolled generalized seizures, especially tonic-clonic seizures, are the most significant risk factor for SUDEP. Sleep deprivation and the presence of a structural lesion (MRI lesion) are less directly correlated, and focal EEG changes are not established as independent risk factors. 1) Uncontrolled generalized tonic-clonic seizures are the single most important risk factor for SUDEP. 2) Nocturnal supervision and seizure detection systems may help mitigate risk in high-risk patients. Recent research continues to emphasize the importance of reducing the frequency of generalized tonic-clonic seizures in lowering SUDEP risk. Guidelines now also recommend a comprehensive approach including patient education on sleep safety and, where applicable, the use of nocturnal monitoring devices.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "35 years old epilepsy on ASM, controlled for the last year, what carriers risk of seizure recurrence in case of medication discontinuation?",
    "option_a": "Generalized seizure",
    "option_b": "Young age of onset",
    "option_c": "? (? Medication compliance)",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Decisions about discontinuing antiepileptic drugs (ASMs) require careful consideration of factors that may predict seizure recurrence. Several clinical factors have been identified that are associated with a greater risk of relapse when therapy is stopped. An early age of onset is thought to reflect an increased inherent excitability or a more robust epileptogenic network that may persist even after a period of seizure freedom. This ongoing susceptibility can predispose patients to relapse once the protective effects of medication are withdrawn. In patients who have achieved seizure control, risk stratification before ASM discontinuation is critical. Individuals with a younger age at seizure onset tend to have a higher rate of recurrence following drug withdrawal, despite a period of remission. Other risk factors often considered include the duration of seizure freedom, EEG findings, and seizure type. Before considering antiepileptic drug discontinuation, a detailed clinical evaluation is recommended. This includes reviewing the seizure history (e.g., age of onset, seizure type, frequency prior to control), a careful EEG (to assess for continuing epileptiform discharges), and ruling out any underlying symptomatic causes. Differential considerations include distinguishing between idiopathic and structural epilepsies. Current guidelines suggest that a minimum of 2 years of seizure freedom is generally required before considering tapering ASMs, and risk factors such as young age at onset should be factored into the decision-making process. A tiered approach involves first ensuring a robust period of remission, re-evaluating EEG findings, and considering patient-specific factors including lifestyle and comorbidities. In pregnancies or women planning conception, abrupt discontinuation is not advised because of the risk posed by seizure recurrence to both mother and fetus. Option B (Young age of onset) is correct in this context because numerous studies have identified it as a predictor of seizure recurrence after medication withdrawal. While a history of generalized seizures is also a recognized risk factor in many scenarios, for this patient the early age at onset stands out as the most relevant consideration given the available options. 1) A longer seizure-free interval (ideally 2\u20135 years) is associated with a lower risk of recurrence upon ASM discontinuation. 2) Abnormal EEG findings during the period of remission are a strong predictor of relapse. Recent reviews and guidelines underscore the importance of individualized risk assessment before ASM withdrawal. Emerging research continues to support the association between early onset and a higher risk of recurrence, advocating for cautious and gradual tapering protocols.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient was diagnosed with epilepsy start on ASM, found to have aplastic anemia, what is the cause?",
    "option_a": "Felbamate",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Felbamate is an antiepileptic medication known for its efficacy in treating refractory seizures, particularly in conditions such as Lennox-Gastaut syndrome. However, its use is limited due to the risk of severe adverse effects, including aplastic anemia and liver failure. Felbamate is associated with idiosyncratic bone marrow suppression that can lead to aplastic anemia. This adverse reaction results from the drug\u2019s potential to damage hematopoietic precursor cells, leading to pancytopenia. The severity of this side effect has led to strict monitoring protocols and limited its use to refractory cases where benefits may outweigh the risks. In the scenario presented, the patient who developed aplastic anemia after starting an ASM is most consistent with felbamate-induced toxicity. Clinical vigilance and regular monitoring of blood counts are required when patients are on felbamate to detect early signs of hematological dysfunction. When a patient with epilepsy develops aplastic anemia, a comprehensive evaluation is needed. Differential diagnoses include aplastic anemia from other causes such as autoimmune disorders, viral infections, or other drug-induced causes. However, in the context of recent ASM initiation and known adverse effect profiles, felbamate is the prime suspect. Due to the risk of life-threatening side effects, felbamate is used only in refractory cases and under strict monitoring for hematologic abnormalities. On identification of aplastic anemia, the drug should be discontinued immediately and supportive care initiated. In women who are pregnant or lactating, felbamate is generally contraindicated due to teratogenic risk and the potential for serious adverse events, necessitating alternative antiepileptic strategies. Option A (Felbamate) is correct. The other options (not provided) would not be associated with aplastic anemia in the context of epilepsy management. Felbamate\u2019s adverse effect profile, including the risk for aplastic anemia, is a well-known contraindication limiting its widespread use. 1) Felbamate is effective in refractory epilepsy but is limited by its serious side effects, including aplastic anemia and hepatic failure. 2) Regular blood count monitoring is essential when a patient is started on felbamate. Recent guideline updates and research have reinforced that due to its adverse effect profile, felbamate is reserved only for cases where other treatments have failed. Newer antiepileptics with safer side effect profiles have largely replaced its use in many clinical scenarios, and current practice emphasizes strict patient selection and monitoring when felbamate is used.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young patient presented with seizure, he denies any aura, brain MRI was normal, he was witnessed to have recurrent generalized tonic clonic seizures, what is the classification for seizure?",
    "option_a": "Generalized onset, motor",
    "option_b": "unknown onset, motor",
    "option_c": "Focal with secondary generalization",
    "option_d": "Focal unaware seizure",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Seizure classification by the International League Against Epilepsy (ILAE) distinguishes seizures based on their onset: focal (originating in one hemisphere) versus generalized (involving both hemispheres from the start) versus unknown onset. Generalized onset seizures are characterized by rapid bilateral involvement without a localized initial symptom such as an aura. Primary generalized seizures arise from abnormal, simultaneous electrical discharges across both hemispheres. The absence of an aura, which would be suggestive of a focal origin, supports a mechanism where the epileptogenic disruption involves widespread bilateral networks from the outset. This is in keeping with the evidence that generalized seizures do not have a localized start point. A young patient with recurrent generalized tonic-clonic seizures and no preceding aura fits the profile of a primary generalized seizure disorder. The normal brain MRI supports the idea that there is no focal lesion precipitating secondary generalization, as might be seen in focal seizures. Differentiation includes ruling out focal onset with secondary generalization, which might present with an aura or focal neurological signs. EEG findings are critical to confirm a generalized pattern. Differential diagnoses include focal seizures (often with an aura or focal deficits) and syncope; however, the repeated generalized tonic-clonic activity and normal imaging help to clarify the diagnosis. First-line management for generalized tonic-clonic seizures generally includes antiepileptic drugs such as valproate, levetiracetam, or lamotrigine, with the choice tailored to the patient\u2019s profile. In women of childbearing potential or during pregnancy/lactation, valproate is typically avoided due to teratogenic risks, favoring levetiracetam or lamotrigine. Dose adjustments and monitoring are essential. Second-line options may be considered in refractory cases. Option A (Generalized onset, motor) is correct. Option B (unknown onset, motor) would be applied if the onset could not be definitively determined. Option C (Focal with secondary generalization) is incorrect because the patient denies any aura or focal signs, which are often present in focal seizures that later generalize. Option D (Focal unaware seizure) is also incorrect as there is no evidence of focal onset or impaired awareness preceding the generalized event. 1. The absence of an aura can reliably point towards a primary generalized seizure. 2. A normal brain imaging study supports a non-lesional, generalized epilepsy diagnosis. 3. EEG remains a key diagnostic tool to confirm bilateral involvement. Recent guidelines emphasize integrating clinical history with EEG findings for seizure classification. Advances in digital EEG and neuroimaging confirm that careful history-taking can often differentiate generalized from focal seizures, directing appropriate first-line therapy.",
    "exam_year": "2024",
    "exam_type": "Part II",
    "image_url": "page_7.png"
  },
  {
    "question": "Child with recurrent stating episodes, myoclonus and rare GTCs, which of the following anti-seizure medications will worsen his seizures?",
    "option_a": "Lamotrigine",
    "option_b": "Oxcarbazepine",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Juvenile myoclonic epilepsy (JME) is one of the common generalized epilepsy syndromes in children and adolescents, characterized by myoclonic jerks, absence (staring) episodes, and sometimes generalized tonic-clonic seizures (GTCs). Correct identification of the syndrome is critical because certain anti-seizure medications are contraindicated. JME involves widespread cortical hyperexcitability with a predisposition for myoclonic jerks, often exacerbated by sodium channel\u2010blocking medications. These drugs can destabilize the neuronal membrane in a way that paradoxically worsens seizure activity in generalized epilepsies, particularly in the presence of a genetic predisposition. The clinical presentation of recurrent staring episodes (consistent with absence seizures), myoclonus, and occasional GTCs is classic for JME. Using medications that act predominantly on sodium channels, such as oxcarbazepine, may provoke or worsen these seizures, impairing seizure control. Diagnosis is based on clinical features, characteristic EEG findings (e.g., generalized polyspike-and-wave discharges), and family history. Differential considerations include absence epilepsy (pure absence seizures), which may have overlapping EEG features but without myoclonic jerks, and focal epilepsies with secondary generalization, which often have an aura or focal deficits. First-line therapy for JME typically includes valproate, levetiracetam, or sometimes lamotrigine, though lamotrigine might increase myoclonic activity in some patients. Oxcarbazepine and other sodium channel blockers (e.g., carbamazepine, phenytoin) are second-line or contraindicated as they can worsen myoclonic and absence seizures. In pregnancy and lactation, valproate is generally avoided due to its teratogenicity, making levetiracetam or careful use of lamotrigine more appropriate. Option B (Oxcarbazepine) is the correct answer as it is known to exacerbate seizures in patients with JME due to its sodium channel blocking effect. Option A (Lamotrigine) is sometimes used in generalized epilepsies but must be used cautiously as it may mildly worsen myoclonus in a subset of patients; however, it is not uniformly contraindicated. The other options are not provided, but based on available information, oxcarbazepine stands out as deleterious. 1. In generalized epilepsies like JME, avoid sodium channel blockers such as oxcarbazepine. 2. Valproate remains highly effective for JME but is less suitable in women of childbearing potential. 3. Levetiracetam is a good alternative with a favorable safety profile in pregnancy. Recent research and updated guidelines reinforce the contraindication of sodium channel blockers in JME and similar generalized epilepsies, emphasizing individualized therapy especially in populations like pregnant women where medication teratogenicity is a major concern.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with aura of Palpitation and sweating, where is the localization?",
    "option_a": "Amygdala",
    "option_b": "Insular",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "Seizure auras often provide localization clues regarding the site of onset. Autonomic auras, which include symptoms such as palpitations and sweating, are typically associated with brain regions responsible for autonomic regulation. The insular cortex plays a key role in autonomic control, integrating visceral sensory input with motor, emotional, and cognitive functions. Seizures originating from the insular region commonly produce dysautonomic symptoms including palpitations, sweating, and gastrointestinal disturbances. A patient who experiences an aura characterized by palpitations and sweating is highly suggestive of an insular seizure. Although the amygdala (located in the mesial temporal lobe) can also be involved in autonomic phenomena, it more frequently produces emotional auras such as fear rather than isolated palpitations and sweating. Localization is aided by correlating clinical aura with EEG and neuroimaging findings. Differential diagnoses include seizures originating in the amygdala, which often present with intense fear or a sense of impending doom, and other autonomic disorders. Detailed history and careful observation during the aura help differentiate insular from temporal lobe seizures. Management of focal seizures, including those with insular onset, involves the use of appropriate anti-seizure medications such as levetiracetam, lamotrigine, or carbamazepine (when not contraindicated). When surgical evaluation is considered in refractory cases, precise localization through advanced imaging and intracranial EEG monitoring is essential. For pregnant or lactating women, levetiracetam and lamotrigine are often preferred due to their better safety profiles. Option B (Insular) is correct because the insular cortex is primarily involved in autonomic regulation. Option A (Amygdala) generally presents with emotional auras (e.g., fear, anxiety) rather than a predominantly autonomic aura. The other options are not provided, making insular the best match based on the described symptoms. 1. Autonomic auras such as palpitations and sweating strongly point to insular involvement. 2. Differentiating insular from amygdala seizures is key, as the latter more commonly involve emotional phenomena. 3. Detailed aura descriptions are invaluable in epilepsy localization. Recent studies support insular involvement in autonomic seizure manifestations. Updated guidelines stress the importance of advanced neuroimaging and EEG in clarifying the exact cortical area involved in autonomic auras.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young man known case of epilepsy his seizure described as starting with laryngeal constriction then reported other symptoms till generalized tonic clonic seizure, where is the localization?",
    "option_a": "Insular",
    "option_b": "?",
    "option_c": "?",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "Seizure auras provide critical clues to the region of onset, with specific symptoms linked to the function of the affected brain area. Laryngeal constriction is a distinctive aura that points toward involvement of cortical regions controlling visceral and sensory inputs related to the throat. The insular cortex is intricately involved in processing visceral sensations and autonomic functions. Seizures originating here can produce a sensation of laryngeal constriction due to the insula\u2019s role in modulating sensory inputs from the throat and related autonomic responses. A seizure that begins with laryngeal constriction, followed by progression to other symptoms and ultimately a generalized tonic-clonic seizure, is indicative of a focal onset seizure with insular involvement. The aura is often the first and most localizing symptom in such cases. Diagnosis involves careful history-taking to capture the precise aura and correlating this with EEG and imaging findings. Differential diagnoses may include seizures from the opercular region which can also cause oro-laryngeal symptoms; however, the insular cortex is more classically associated with laryngeal constriction. Distinguishing these entities may require advanced techniques such as intracranial EEG. Management of focal seizures with insular onset involves selecting appropriate anti-seizure medications (e.g., levetiracetam, lamotrigine) and considering surgical options if the seizures are drug-resistant. In pregnant or lactating patients, therapy should be chosen based on safety profiles; levetiracetam is often favored. A tiered approach typically starts with monotherapy and adjusts based on response and side effects. Option A (Insular) is correct because laryngeal constriction is a hallmark of insular seizures. Other potential options are not provided, but based on clinical symptomatology, the insula is the region most consistent with this aura type. 1. Laryngeal constriction as an aura strongly suggests involvement of the insular cortex. 2. Detailed descriptions of auras can be crucial for precise localization of seizure onset. 3. Insular seizures often require a detailed workup including advanced EEG and imaging. Recent research involving functional imaging and intracranial monitoring has reinforced the correlation between insular activation and autonomic as well as laryngeal auras. Updated guidelines continue to support tailored treatment based on seizure localization.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Young Lady with epilepsy on lamotrigine want to start OCP, what should you recommend for her?",
    "option_a": "No effect by OCP, she can start",
    "option_b": "Lamotrigine will decrease efficacy of OCP",
    "option_c": "Increase Lamotrigine by 2 folds",
    "option_d": "Increase Lamotrigine by 4 folds",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Epilepsy",
    "explanation": "This question focuses on the well\u2010known pharmacokinetic interaction between lamotrigine and estrogen\u2010containing oral contraceptives. Estrogens induce the enzymes responsible for lamotrigine metabolism, leading to lower serum levels which can compromise seizure control. Estrogen in OCPs enhances the activity of uridine diphosphate glucuronosyltransferases (UGTs), significantly increasing the clearance of lamotrigine. As serum levels drop (often by as much as 50%), the patient may become at risk for breakthrough seizures unless the lamotrigine dose is appropriately adjusted. In a woman with epilepsy who is stable on lamotrigine, starting an OCP without adjusting the medication can lead to subtherapeutic lamotrigine concentrations and potential loss of seizure control. Monitoring for breakthrough seizures and, if needed, checking drug levels helps guide dose adjustments. Monitoring serum lamotrigine levels and clinical observation for breakthrough seizures are essential when changes in concomitant medications (such as starting OCPs) occur. Differential considerations include poor medication adherence or other drug interactions that might lower lamotrigine levels. According to the latest guidelines, when a patient on lamotrigine initiates an estrogen\u2010containing OCP, clinicians should anticipate a reduction in lamotrigine serum levels. The first tier of management is to monitor for clinical signs of breakthrough seizures and measure lamotrigine levels. If levels drop significantly, a typical strategy is to increase the lamotrigine dose by about 2-fold (with careful titration) while being mindful of risks when the OCP is stopped. In pregnancy or lactation, lamotrigine is considered one of the safer antiseizure medications but also requires careful monitoring due to its variable levels. Option A is incorrect as there is a significant drug interaction; Option B is incorrect because lamotrigine does not decrease the efficacy of the OCP \u2013 rather, the OCP increases lamotrigine clearance; Option C (increase lamotrigine by 2 folds) is correct given the magnitude of enzyme induction typically observed; Option D is an overcorrection and not supported by evidence. 1. Estrogen-containing OCPs can lower lamotrigine levels by up to 50%, risking breakthrough seizures. 2. Always review potential drug interactions when managing women with epilepsy. 3. Monitor serum levels and clinical response when initiating or discontinuing OCPs in lamotrigine-treated patients. Recent studies and updated guidelines emphasize the importance of monitoring lamotrigine concentrations when starting OCPs and recommend dose adjustment rather than switching medications. The approach is individualized based on clinical response and serum level measurements.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with recurrent episodes of staring followed by ringing tone and rare GTCs, has brother with similar condition, what is the gene?",
    "option_a": "GABRA1",
    "option_b": "LGI 1",
    "option_c": "KCNQ1",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "This question assesses knowledge of genetic causes underlying familial focal epilepsies. Specifically, it targets autosomal dominant lateral temporal lobe epilepsy (ADLTE), which typically presents with auditory auras such as a ringing tone. Mutations in the LGI1 gene lead to abnormal synaptic transmission in the lateral temporal lobes. LGI1 plays a role in modulating neuronal excitability and synaptic stability, and its mutation disrupts this balance, leading to focal seizures with auditory symptoms. Patients with LGI1 mutations often present with focal seizures accented by auditory auras (eg, a ringing tone) and may exhibit a positive family history, as in autosomal dominant inheritance patterns. The presence of similar symptoms in a sibling further supports the genetic basis. The diagnostic workup includes a detailed family history and seizure semiology. Differential diagnoses include other genetic epilepsies linked to different genes (eg, GABRA1) but these generally have distinct clinical features. Genetic testing and EEG findings can also help confirm the diagnosis. Management of seizures in ADLTE follows the general approach to focal epilepsies with first-line agents such as lamotrigine, carbamazepine, or levetiracetam. Genetic counseling is important for affected families. In women of childbearing age, drug selection should consider teratogenic risks; lamotrigine is generally preferred in pregnancy with appropriate monitoring and folate supplementation. Option A (GABRA1) is usually associated with other epileptic syndromes rather than auditory auras; Option B (LGI1) is correct as it is strongly linked to ADLTE; Option C (KCNQ1) is primarily associated with cardiac conditions (long QT syndrome) and is not a recognized cause of this type of epilepsy. 1. A ringing tone or auditory aura in the context of familial epilepsy strongly points toward an LGI1 mutation. 2. ADLTE is generally inherited in an autosomal dominant pattern. 3. Genetic testing can be key in confirming the diagnosis in familial cases. Recent genetic research has solidified LGI1\u2019s role in ADLTE, and updated clinical guidelines recommend considering genetic evaluation in familial focal epilepsies. New insights into LGI1 have also prompted investigations into targeted therapies that address synaptic dysfunction.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient was brought by from dental clinic unconscious, in the emergency patient woke up, what will support the diagnosis of seizure rather than syncope?",
    "option_a": "Cyanosis",
    "option_b": "Multifocal myoclonus",
    "option_c": "No post ictal confusion",
    "option_d": "Intense pain before the event",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Epilepsy",
    "explanation": "The challenge in this scenario is differentiating a seizure from a syncope episode based on post-event findings. Seizures typically exhibit features like postictal confusion and myoclonic jerks, whereas syncope is characterized by a quick recovery. Seizures result from abnormal, synchronized neuronal discharges, which often trigger widespread motor phenomena such as multifocal myoclonus in the postictal period. Syncope, caused by transient cerebral hypoperfusion, does not involve the same level of neuronal excitation. The presence of multifocal myoclonus after an event is more characteristic of a seizure as the motor cortex recovers from the abnormal discharge. Syncope usually results in pallor with a rapid return to baseline neurological function without such motor phenomena. Key differentials include vasovagal syncope (often associated with prodromal symptoms, pallor, rapid recovery) and epileptic seizures (typically followed by postictal confusion, myoclonic jerks, tongue biting, and incontinence). The most reliable distinguishing feature is the presence of postictal phenomena specific to seizures. The evaluation of transient loss of consciousness should include a detailed history and witness accounts, with EEG and cardiovascular workup used to differentiate between seizures and syncope. In the case of seizures, once the diagnosis is confirmed, management includes starting appropriate antiepileptic treatment. In pregnant or lactating patients, careful selection of medications with favorable safety profiles is essential (lamotrigine is an example). Option A (Cyanosis) is a non\u2010specific finding and may be seen in both syncope and seizures; Option B (Multifocal myoclonus) is strongly supportive of a seizure due to the involvement of widespread motor activation; Option C (No postictal confusion) would actually favor a diagnosis of syncope; Option D (Intense pain before the event) is more typical of vasovagal syncope triggered by pain. 1. Multifocal myoclonus after an event is a key sign of a true seizure. 2. Rapid recovery without confusion suggests syncope. 3. Detailed eyewitness accounts are invaluable in differentiating these conditions. Contemporary studies emphasize that postictal motor phenomena and confusion are more reliable in differentiating seizures from syncope than isolated signs like cyanosis. Video-EEG monitoring is recommended in ambiguous cases to capture and clarify the event characteristics.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "A 45-year-old patient known case of DM and HTN came with new onset seizure, brain MRI attached showed left temporal lesion (Picture of Cavernoma), what is the most appropriate next step?",
    "option_a": "Start lamotrigine",
    "option_b": "Refer to neurosurgery",
    "option_c": "EEG",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Epilepsy",
    "explanation": "This question involves the management of a patient with a structural lesion\u2014a cavernoma in the temporal lobe\u2014that has presented with a new-onset seizure. The initial management of such symptomatic structural epilepsy is first-line medical therapy. Cavernomas are vascular malformations composed of dilated capillary channels that can cause local irritation, microhemorrhages, or gliosis in adjacent brain tissue. These changes can lower the seizure threshold, particularly in sensitive areas such as the temporal lobe. A lesion in the left temporal region correlates with the semiology of focal seizures. Even though the structural abnormality is clearly identified on MRI, the first reaction is to control seizures medically before considering surgical options, unless hemorrhagic events or refractory seizures occur. The MRI finding of a cavernoma\u2014often described as having a 'popcorn' appearance with a surrounding hemosiderin rim\u2014confirms the structural cause of the seizures. Differential diagnoses include neoplasms, arteriovenous malformations, and other forms of vascular malformations. EEG can assist in characterizing the seizure type but is not immediately critical to management. The current tiered management approach is to begin first-line anti-epileptic drug (AED) therapy\u2014in this case, lamotrigine is a reasonable choice given its efficacy in focal epilepsies and favorable side effect profile. Neurosurgical referral is typically reserved for patients with medically refractory seizures or if there is evidence of recurrent hemorrhage. In women of childbearing age or during pregnancy/lactation, lamotrigine is preferred due to a lower teratogenic profile, though levels must be monitored due to possible pharmacokinetic changes (especially with OCP use). Option A (Start lamotrigine) is the appropriate first-line management for seizure control. Option B (Refer to neurosurgery) would be considered in refractory cases or if the lesion presents with significant hemorrhagic risk. Option C (EEG) is valuable for further characterization but is not the immediate next step in acute management; Option D is not provided. 1. In new-onset seizures due to a structural lesion, medical management is the initial step. 2. Lamotrigine is often preferred in focal epilepsies due to its safety profile. 3. Surgical intervention is reserved for cases where seizures are refractory to optimal medical management. Recent guidelines advocate for starting antiepileptic drugs upon the first seizure in the context of a clear structural lesion if the patient experiences recurrent events. Studies have supported lamotrigine\u2019s efficacy in focal epilepsies and its relatively safe profile in special populations such as pregnant or lactating women, with close attention to serum level monitoring.",
    "exam_year": "2024",
    "exam_type": "Part II",
    "image_url": "page_6.png"
  }
]